 EDISON, N.J., July 23, 2021 GLOBE NEWSWIRE -- Hepion Pharmaceuticals, Inc. NASDAQ:HEPA, a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis NASH, today announced the postponement of its adjourned 2021 Annual Meeting of Stockholders the Annual Meeting that was to be held on July 23, 2021, at 9:00 a.m. Eastern Time due to a lack of a quorum. The meeting will be rescheduled for a date yet to be determined by the Board of Directors. The Board of Directors will establish a new record date for the Annual Meeting and, based on this record date, the Company will deliver a notice of the new Annual Meeting date to stockholders entitled to receive notice of the Annual Meeting. 